Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.
Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
People Thought This Arby’s Had a Random Fancy Table — Then Veterans Explained Its Powerful Meaning
Rare “Deadliest Cat in Africa” Kitten Born at Texas Zoo
This Tiny Blue Octopus Was Found 5,800 Feet Beneath the Ocean — and Scientists Had Never Seen Anything Like It
Swan Trusts Photographer Enough to Introduce Him to Her Eggs and Then Her Babies
Deaf Woman Brought to Tears by Glasses That Let Her Read Conversations in Real Time
Hiker Hears Faint Cries, Finds Ram Stuck Deep in Mud
High School Surprises 90-Year-Old Janitor With Heartwarming Birthday Assembly
Wife Proudly Shows Husband Cooking Breakfast for Workers Renovating Their Home
Mom Diagnosed With Terminal Cancer While Pregnant Shares Emotional Dance With Daughter 3 Years Later
